Effects of Sugary Drinks Counter-marketing Messages

February 26, 2024 updated by: Anna Grummon, Stanford University

Effects of Anti-sugar-sweetened-beverage Counter-marketing on Behavioral Intentions and Perceived Weight Stigma

This study aims to examine consumer responses to traditional and counter-marketing messages discouraging sugary drink consumption, including effects on intentions to consume sugary drinks and perceived weight stigma. Because prior research has suggested that counter-marketing may be especially effective among younger populations, the investigators will examine effects overall and by age group (young adults [ages 18-29 years] vs. middle and older adults [ages 30+ years]).

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

In this online randomized clinical trial, participants will be randomized to one of three arms: 1) Control (neutral) messages, 2) Traditional health messages, and 3) Counter-marketing messages. In each arm, participants will view four messages developed for their randomly assigned arm and answer questions about the messages and their behavioral intentions.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
2184

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • United States
    • California
      • Palo Alto, California, United States, 94304
        • Stanford School of Medicine

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • 18 years old or older

Exclusion Criteria:

  • Less than 18 years old

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Traditional health messages
Participants will view traditional health messages focused on the health consequences of sugar-sweetened beverage consumption, using text adapted from prior sugary drink campaigns. Participants will view a total of 4 messages developed for this arm.
Behavioral: Exposure to traditional health messages
Traditional health messages focused on the health consequences of sugar-sweetened beverage consumption, using text adapted from prior sugary drink campaigns. Participants will view a total of 4 messages developed for this arm.
Active Comparator: Control (neutral) messages
Participants will view control messages approximately matched to the intervention messages on length, but discussing a neutral topic unrelated to sugary drinks (safe driving). Participants will view a total of 4 messages developed for this arm.
Behavioral: Exposure to control (neutral) messages
Control messages approximately matched to the intervention messages on length, but discussing a neutral topic unrelated to sugary drinks (safe driving). Participants will view a total of 4 messages developed for this arm.
Experimental: Counter-marketing messages
Participants will view counter-marketing messages about sugary drinks that incorporate principles of effective counter-marketing campaigns, including describing industry manipulation of consumers, appealing to emotions (especially anger), describing health consequences, and criticizing the industry for demographic targeting. Messages include text adapted from prior counter-marketing campaigns. Participants will view a total of 4 messages developed for this arm.
Behavioral: Exposure to counter-marketing messages
Counter-marketing messages about sugary drinks that incorporate principles of effective counter-marketing campaigns, including describing industry manipulation of consumers, appealing to emotions (especially anger), describing health consequences, and criticizing the industry for demographic targeting. Messages include text adapted from prior counter-marketing campaigns. Participants will view a total of 4 messages developed for this arm.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Intentions to consume sugary drinks
Time Frame: The survey will take up to 20 minutes
We will assess intentions to consume sugary drinks using 2 items: "In the next week, I plan to drink sugary drinks like sodas, sports drinks, or fruit drinks," and "In the next week, I am likely to drink sugar-sweetened beverages like sodas, sports drinks, or fruit drinks". Response options to both items will use a 5-point Likert scale: the first item's response options will range from "definitely not" (1) to "definitely yes" (5), and the second item's response options will range from "not at all likely" (1) to "extremely likely" (5). We will average responses to the 2 items.
The survey will take up to 20 minutes

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Perceived message effectiveness for discouraging sugary drink consumption
Time Frame: The survey will take up to 20 minutes
Item: "These messages discourage me from wanting to drink sugary drinks." This variable will be measured on a 5-point Likert scale ranging from "not at all" (1) to "a great deal" (5).
The survey will take up to 20 minutes
Negative feelings toward drinking sugary drinks
Time Frame: The survey will take up to 20 minutes
Item: "How do these messages make you feel about drinking sugary drinks?" This variable will be measured on a 5-point Likert scale ranging from "extremely positive" (1) to "extremely negative" (5).
The survey will take up to 20 minutes
Anticipated social interactions
Time Frame: The survey will take up to 20 minutes
We will examine anticipated social interactions by asking, "How likely are you to talk about these messages with others in the next week?" This item will be scored on a 5-pt Likert scale ranging from "not at all likely" (1) to "extremely likely" (5).
The survey will take up to 20 minutes
Attitudes toward sugary drink companies
Time Frame: The survey will take up to 20 minutes
We will examine attitudes toward sugary drink companies by asking, "How do you feel about companies that make sugary drinks?" This item will be scored on a 5-pt Likert scale ranging from "dislike them a lot" (1) to "like them a lot" (5).
The survey will take up to 20 minutes
Perceived obesity stigma
Time Frame: The survey will take up to 20 minutes
We will examine the extent to which participants perceive the messages as contributing to obesity stigma by asking 3 items: "These messages promote negative attitudes about people who have overweight or obesity," "These messages increase blame towards people for being overweight," and "These messages make obesity seem like a much simpler issue than it really is." Each item will be scored on a 5-point Likert scale from "not at all" (1) to "a great deal" (5). We will average responses to these items.
The survey will take up to 20 minutes
Message reactance
Time Frame: The survey will take up to 20 minutes
We will examine psychological reactance to the messages by asking 3 items: "These messages are trying to manipulate me," "These messages are overblown" and "How much do these messages make you feel angry?" Each item will be scored on a 5-point Likert scale from "not at all" (1) to "a great deal" (5). We will average responses to these items, assuming sufficient internal consistency (alpha>=.70).
The survey will take up to 20 minutes

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Stanford University

Collaborators

Collaborators

An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.
Harvard Pilgrim Health Care

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Anna H Grummon, PhD, Stanford School of Medicine, Department of Pediatrics

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
August 7, 2023

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
August 7, 2023

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
August 7, 2023

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
July 11, 2023

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
July 11, 2023

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
July 20, 2023

Study Record Updates

Last Update Posted (Estimated)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
February 28, 2024

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
February 26, 2024

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
February 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 69580a

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

The investigators will share statistical analysis plan and analytic code after publication. The investigators will post these items and de-identified data on ResearchBox, a publicly available platform.

IPD Sharing Time Frame

Within 6 months of publication

IPD Sharing Access Criteria

There will be no access criteria; information will be publicly available. We plan to make these resources available on ResearchBox.

IPD Sharing Supporting Information Type

  • SAP
  • ANALYTIC_CODE

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings